What's happened
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
What's behind the headline?
Context and caution
- This update consolidates several studies suggesting a link between GLP-1 therapies and alopecia, often tied to weight loss and possible micronutrient deficiencies as patients reduce caloric intake.
- The issue is not uniformly observed across all GLP-1 drugs; tirzepatide may carry higher reported risk in some analyses, with thyroid or endocrine factors possibly modulating risk.
- Policy and clinical guidance are evolving as regulators review signals and industry trials continue.
Key implications
- Clinicians should counsel patients on potential hair-loss risks, especially those with underlying thyroid or endocrine issues.
- Weight-management expectations and nutritional support should be emphasized during GLP-1 therapy.
- Further research is needed to disentangle drug-specific effects from weight-loss physiology and comorbidities.
How we got here
The BMJ study analyzes hair-loss signals among 12,004 GLP-1 users, 15,221 SGLT-2 users, and 11,964 additional GLP-1 users compared to 11,233 DPP-4 users, adjusting for age and weight. Regulators in the US have acknowledged case reports, and the UK MHRA has logged dozens of hair-loss reports linked to tirzepatide and semaglutide in 2026.
Our analysis
Independent, New York Post, CNBC; BMJ study cited; regulatory apps note US FDA review and UK MHRA reports.
Go deeper
- What does this mean for ongoing GLP-1 therapy?
- Are there specific patient groups at higher risk?
- What are the next steps regulators will require?
More on these topics
-
semaglutide - Medication
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...